Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company
with a novel platform technology for the oral delivery of drugs
currently only available via injection, announced today that Dr.
Michael Berelowitz, M.D., has been appointed the Chairman of its
Scientific Advisory Board (SAB).

Dr. Berelowitz joined Oramed's Board of Directors in May 2010
and will now expand his role as Chairman of the SAB. Moving
forward, he will be actively involved in the
Company's scientific decisions, clinical strategy, and
partnership negotiations.

Dr. Berelowitz has extensive experience as an academic
endocrinologist as well as expertise in clinical research and drug
development. Most recently, he served as the Senior Vice
President and Head of Clinical Development and Medical Affairs in
the Specialty Care Business Unit at Pfizer. Dr. Berelowitz
joined Pfizer in 1996, after several years in academia, as a
Medical Director on the Diabetes Disease Management Team. Among his
public activities, Dr. Berelowitz has served on the board of
directors of the American Diabetes Association and the Clinical
Initiatives Committee of the Endocrine Society. He has also
chaired the Task Force on Research of the New York State Council on
Diabetes and has served on several editorial boards. Dr. Berelowitz
has authored and co-authored more than 100 peer-reviewed journal
articles and book chapters in the areas of pituitary growth hormone
regulation, diabetes and metabolic disorders.

"Dr. Berelowitz is a renowned industry leader with a special
interest in and knowledge of diabetes. His expertise in this
expanded role will be invaluable as Oramed continues to advance its
clinical trials and business development efforts," said Nadav
Kidron, Chief Executive Officer of Oramed.

Dr. Berelowitz commented, "I am honored and excited about my new
role at Oramed. Since joining the Board of Directors in 2010, I
have had a chance to get to know the management team and work
closely with them towards achieving their goals. I look
forward to helping the company progress and develop novel therapies
to serve the large and growing numbers of people who suffer from
diabetes. "

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs and vaccines presently delivered
via injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research performed by top research scientists at Jerusalem's
Hadassah Medical Center. The Company's corporate and R&D
headquarters are based in Jerusalem.

Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements.